Soleymani S - Search Results

1

Dark kinase annotation, mining, and visualization using the Protein Kinase Ontology.

Soleymani S, Gravel N, Huang LC, Yeung W, Bozorgi E, Bendzunas NG, Kochut KJ, Kannan N. Soleymani S, et al. PeerJ. 2023 Dec 5;11:e16087. doi: 10.7717/peerj.16087. eCollection 2023. PeerJ. 2023. PMID: 38077442 Free PMC article.

2

GTXplorer: A portal to navigate and visualize the evolutionary information encoded in fold A glycosyltransferases.

Taujale R, Soleymani S, Priyadarshi A, Venkat A, Yeung W, Kochut KJ, Kannan N. Taujale R, et al. Among authors: soleymani s. Glycobiology. 2021 Dec 18;31(11):1472-1477. doi: 10.1093/glycob/cwab082. Glycobiology. 2021. PMID: 34351427 Free PMC article.

3

Phosformer: an explainable transformer model for protein kinase-specific phosphorylation predictions.

Zhou Z, Yeung W, Gravel N, Salcedo M, Soleymani S, Li S, Kannan N. Zhou Z, et al. Among authors: soleymani s. Bioinformatics. 2023 Feb 3;39(2):btad046. doi: 10.1093/bioinformatics/btad046. Bioinformatics. 2023. PMID: 36692152 Free PMC article.

4

Using explainable machine learning to uncover the kinase-substrate interaction landscape.

Zhou Z, Yeung W, Soleymani S, Gravel N, Salcedo M, Li S, Kannan N. Zhou Z, et al. Among authors: soleymani s. Bioinformatics. 2024 Feb 1;40(2):btae033. doi: 10.1093/bioinformatics/btae033. Bioinformatics. 2024. PMID: 38244571 Free PMC article.

5

Engendered nanoparticles for treatment of brain tumors.

Soleymani S, Doroudian M, Soezi M, Beladi A, Asgari K, Mobarakshahi A, Aghaeipour A, Macloughlin R. Soleymani S, et al. Oncol Res. 2024 Dec 20;33(1):15-26. doi: 10.32604/or.2024.053069. eCollection 2025. Oncol Res. 2024. PMID: 39735671 Free PMC article. Review.

6

Electrical vehicles impact on unbalanced distribution networks considering different loads and energy prices.

Sadat SMAM, Mohammadnezhad Shourkaei H, Soleymani S. Sadat SMAM, et al. Among authors: soleymani s. Heliyon. 2024 Oct 10;10(21):e39233. doi: 10.1016/j.heliyon.2024.e39233. eCollection 2024 Nov 15. Heliyon. 2024. PMID: 39583817 Free PMC article.

7

ALTERNATIVE THERAPEUTIC APPROACHES FOR PARALYTIC ILEUS IN PERSIAN MEDICINE.

Shahrestani S, Soleymani S, Khadem E, Shahrestani S, Niktabe Z, Ghorat F. Shahrestani S, et al. Among authors: soleymani s. Acta Med Hist Adriat. 2024 Jul 15;22(1):111-128. doi: 10.31952/amha.22.1.5. Acta Med Hist Adriat. 2024. PMID: 39580653

8

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi FS. Long GV, et al. Among authors: soleymani s. J Clin Oncol. 2024 Nov 6:JCO2400400. doi: 10.1200/JCO.24.00400. Online ahead of print. J Clin Oncol. 2024. PMID: 39504507

9

Circulating Tumor Cells in Cancer Diagnosis, Therapy, and Theranostics Applications: An Overview of Emerging Materials and Technologies.

Soleymani S, Naghib SM, Mozafari MR. Soleymani S, et al. Curr Pharm Des. 2024 Oct 29. doi: 10.2174/0113816128328459241009191933. Online ahead of print. Curr Pharm Des. 2024. PMID: 39473210

10

Reply to the Letter to the Editor "Reflections on the statistical methodology in nivolumab and ipilimumab therapy research" by S. Yang.

Melero I, Soleymani S, Tschaika M, El-Khoueiry AB. Melero I, et al. Among authors: soleymani s. Ann Oncol. 2024 Sep;35(9):827-828. doi: 10.1016/j.annonc.2024.07.719. Ann Oncol. 2024. PMID: 39214632 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters